타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Epkinly (epcoritamab) |
Overview Company | Genmab / AbbVie |
Overview Modality | ANTIBODY |
Overview Target | CD20 × CD3 |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. |
Positioning Known limitation | CD20 antigen loss and exhausted effector T cells after multiple prior lines. |
Positioning Development positioning | 3L+ |
MoA Mechanism | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. |
MoA Biomarker | CD20 expression; ctDNA MRD investigational. |
Toxicology Major finding | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. |
Toxicology CRS | CRS ~50%, grade ≥3 ~2.5% |
Clinical Safety signal | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Epkinly (epcoritamab) |
Overview Company | Genmab / AbbVie |
Overview Modality | ANTIBODY |
Overview Target | CD20 × CD3 |
Overview Indication | Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Subcutaneous dosing gives slower Cmax and lower grade ≥3 CRS than IV engagers. |
Positioning Known limitation | CD20 antigen loss and exhausted effector T cells after multiple prior lines. |
Positioning Development positioning | 3L+ |
MoA Mechanism | Bispecific binding of CD20 on B cells and CD3 on T cells creates a cytolytic synapse; the silenced Fc prevents Fcγ-receptor-driven off-target activation. |
MoA Biomarker | CD20 expression; ctDNA MRD investigational. |
Toxicology Major finding | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. |
Toxicology CRS | CRS ~50%, grade ≥3 ~2.5% |
Clinical Safety signal | Boxed warning for CRS and ICANS. Injection-site reactions, neutropenia, and infection are common. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교